Cited 5 time in
Propofol Alone versus Propofol in Combination with Midazolam for Sedative Endoscopy in Patients with Paradoxical Reactions to Midazolam
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Nam, Ji Hyung | - |
| dc.contributor.author | Jang, Dong Kee | - |
| dc.contributor.author | Lee, Jun Kyu | - |
| dc.contributor.author | Kang, Hyoun Woo | - |
| dc.contributor.author | Kim, Byung-Wook | - |
| dc.contributor.author | Jang, Byung Ik | - |
| dc.date.accessioned | 2023-04-27T12:40:57Z | - |
| dc.date.available | 2023-04-27T12:40:57Z | - |
| dc.date.issued | 2022-03 | - |
| dc.identifier.issn | 2234-2400 | - |
| dc.identifier.issn | 2234-2443 | - |
| dc.identifier.uri | https://scholarworks.dongguk.edu/handle/sw.dongguk/3510 | - |
| dc.description.abstract | Background/Aims: The efficacy of propofol in gastrointestinal endoscopy for patients with midazolam-induced paradoxical reactions remains unclarified. This study aimed to compare the efficacy and safety of propofol-based sedation in patients who previously experienced paradoxical reactions. Methods: This was a prospective, single-blinded, randomized controlled pilot study. Participants with a history of paradoxical reactions to midazolam during a previous esophagogastroduodenoscopy were recruited and randomly assigned to group I (propofol monosedation) or group II (combination of propofol and midazolam). The primary endpoint was the occurrence of a paradoxical reaction. Results: A total of 30 participants (mean age, 54.7 +/- 12.6 years; male, 19/30) were randomly assigned to group I (n=16) or group II (n=14). There were no paradoxical reactions in group I, but there were two in group II, without a significant difference (p=0.209). The mean dose of propofol was higher in group I than in group II (p=0.002). Meanwhile, the procedure and recovery times did not differ between groups. Conclusions: Propofol-based sedation was safe and effective for patients who experienced paradoxical reactions to midazolam. However, caution is needed because few cases of paradoxical reaction again can happen in group II in which midazolam was readministered. | - |
| dc.format.extent | 6 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | 대한소화기내시경학회 | - |
| dc.title | Propofol Alone versus Propofol in Combination with Midazolam for Sedative Endoscopy in Patients with Paradoxical Reactions to Midazolam | - |
| dc.type | Article | - |
| dc.publisher.location | 대한민국 | - |
| dc.identifier.doi | 10.5946/ce.2021.126 | - |
| dc.identifier.scopusid | 2-s2.0-85128266557 | - |
| dc.identifier.wosid | 000735212000001 | - |
| dc.identifier.bibliographicCitation | Clinical Endoscopy, v.55, no.2, pp 234 - 239 | - |
| dc.citation.title | Clinical Endoscopy | - |
| dc.citation.volume | 55 | - |
| dc.citation.number | 2 | - |
| dc.citation.startPage | 234 | - |
| dc.citation.endPage | 239 | - |
| dc.type.docType | Article | - |
| dc.identifier.kciid | ART002827295 | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.description.journalRegisteredClass | esci | - |
| dc.description.journalRegisteredClass | kci | - |
| dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
| dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
| dc.subject.keywordPlus | GASTROINTESTINAL ENDOSCOPY | - |
| dc.subject.keywordPlus | BALANCED PROPOFOL | - |
| dc.subject.keywordPlus | MODERATE SEDATION | - |
| dc.subject.keywordPlus | BENZODIAZEPINES | - |
| dc.subject.keywordAuthor | Endoscopy | - |
| dc.subject.keywordAuthor | Midazolam | - |
| dc.subject.keywordAuthor | Paradoxical reaction | - |
| dc.subject.keywordAuthor | Propofol | - |
| dc.subject.keywordAuthor | Sedation | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
30, Pildong-ro 1-gil, Jung-gu, Seoul, 04620, Republic of Korea+82-2-2260-3114
Copyright(c) 2023 DONGGUK UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
